Analyst ratings are aggregated from multiple third-party sources and may be inaccurate, incomplete, or outdated. All ratings remain the sole responsibility of their original providers. Rankings are based on the 3-year performance of a simulated $100,000 account trading on analyst ratings data.
| Trades 471 | Longs Won 208/437 47% | Profit Factor 0.92 |
| Profitability | Shorts Won 10/34 29% | Standard Deviation $3,887.49 |
| Average Win $999.18 | Best Trade (Jun 28) $41,074.63 | Sharpe Ratio -98.79 |
| Average Loss -$940.03 | Worst Trade (Jul 24) -$36,659.17 | Z-Score -5.82 (100%) |
| Commissions $0 | Avg. Trade Length 2m 6d | Expectancy -$42.47 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | - | - | - | - | - | - | - | - | - | - |
| Consecutive Losing Trades | 85 | 77 | 68 | 60 | 51 | 43 | 34 | 26 | 17 | 9 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
RARE Ultragenyx Pharmaceutical Inc. | 3,095.81 | $79,995.84 | $79,995.84 | - | - | - | +2.054% |